市場調查報告書
商品編碼
1279009
維生素 K 市場:按類型、應用、給藥途徑、分銷渠道和預測,2023-2032 年Vitamin K Market - By Type, By Application, By Route of Administration, By Distribution Channel & forecast, 2023 - 2032 |
在對維生素補充劑的高需求的推動下,預計從 2023 年到 2032 年,全球維生素 K 市場將以溫和的速度增長。
人們對維生素補充劑益處的認識不斷提高預計將促進該行業的發展。 大量臨床數據支持維生素對一般健康的重要性及其對人體(尤其是骨骼)的益處,從而提高了人們對克服維生素 K 缺乏症和相關疾病的認識和需求。 因此,注射劑、口服補充劑和膳食補充劑等維生素 K 類產品的銷售額顯著增加。
除此之外,藥物輸送系統的持續技術創新將進一步加速市場的增長。 生物製品行業的積極前景和藥物自我管理的引入將在 2023-2032 年刺激對維生素 K 的需求。
維生素 K 市場按應用、給藥途徑、分銷渠道和地區劃分。
到 2022 年,維生素 K 缺乏性出血 (VKDB) 應用領域的維生素 K 市場價值將超過 1.9 億美元,到 2032 年將具有巨大的吸引力。 維生素 K 缺乏症 在嬰兒中,維生素 K 缺乏症會導致出血。 根據疾病控制和預防中心的數據,早期和經典 VKDB 更為常見,每 60 至 250 名新生兒中就有 1 人受到影響,而晚期 VKDB 則較為罕見,每 14,000 至 1,000 名新生兒中就有 1 人受到影響。每 25,000 名兒童中就有 1 人受到影響。 腸道、大腦和身體其他部位的出血在患有 VKDB 的嬰兒中很常見,這被認為是導致對該產品需求增加的原因。
從給藥途徑來看,口服維生素 K 市場將在 2032 年增長,原因是患者的接受度和舒適度、非侵入性、可負擔性以及大規模生產的便利性。預計將有很高的採用率率直到 隨著慢性病發病率的增加,口服給藥的使用率增加,這支持了該細分市場的擴張。
根據分銷渠道,線下細分市場的維生素 K 市場份額預計將在 2023 年至 2032 年間呈指數級增長。 分銷商、批發商和零售商等線下渠道用於將產品分銷給目標客戶。 線下分銷渠道包括大賣場、超市、專賣店和藥店。 預計為客戶提供更廣泛的各種產品選擇將推動該細分市場的增長。
按地區劃分,亞太地區的維生素 K 市場預計將以超過 10.5% 的複合年增長率增長。 2023 年至 2032 年的複合年增長率為 5%。 不斷上升的生育率和不斷增長的老年人口增加了維生素補充劑的流行和可用性,推動了市場擴張。 此外,亞太國家見證了全球競爭對手的存在,以及政府在醫療保健研發方面的支出不斷增加,預計這將推動該地區的市場增長。
Global Vitamin K Market is set to expand at a decent growth rate from 2023 to 2032, driven by the high demand for vitamin supplements.
Rising awareness of the advantages of vitamin supplements is projected to contribute to the industry growth. A substantial amount of clinical data supports the significance of vitamins in general health and their benefits to the human body, particularly the bones, leading to increased awareness and demand for vitamin K to overcome deficiencies and related disorders. As a result, the sales of vitamin K-based products such as injections, oral supplements, and dietary supplements has grown substantially.
This apart, the consistent technological innovations in the medication delivery system will further accelerate market growth. The positive outlook of the biologics sector and the introduction of medication self-administration will stimulate the demand for vitamin K over 2023-2032.
The vitamin K market is segmented as per application, route of administration, distribution channel, and region.
The vitamin K market from the Vitamin K deficiency bleeding (VKDB) application segment was valued at over USD 190 million in 2022 and is poised to gain significant traction through 2032. A lack of vitamin K In babies, a deficiency of vitamin K causes bleeding. As per the Centers for Disease Control and Prevention, early and classical VKDB is more common, affecting 1 in 60 to 1 in 250 neonates, but late VKDB is uncommon, affecting 1 in 14,000 to 1 in 25,000 children. Bleeding inside the body, such as the intestines or brain, is prevalent in babies with VKDB, which may contribute to the rising product demand.
By route of administration, the vitamin K market from the oral segment is projected to witness a high adoption rate through 2032 due to its several benefits, such as patient acceptance and comfort, non-invasiveness, affordability, and convenience of manufacturing on a large scale. As the frequency of chronic illnesses rises, the usage of oral administration will increase, thereby supporting segment expansion.
Based on the distribution channel, the vitamin K market share from the offline segment is estimated to grow exponentially between 2023 and 2032. Offline channels, such as distributors, wholesalers, and retailers, are used to distribute the product to the target customers. Offline distribution channels include hypermarkets, supermarkets, specialized stores, and pharmacy stores. The widespread availability of a range of product options to customers is likely to facilitate segment growth.
Regionally, the Asia Pacific vitamin K market is anticipated to grow at more than 10. 5% CAGR over 2023-2032. The increasing birth rate and rise in the geriatric population have increased the adoption rate and availability of vitamin supplements, thereby driving market expansion. Furthermore, the strong presence of global competitors throughout APAC nations, in line with rising government spending for healthcare R&D, will promote regional market growth.